Research > ETFs > ETF / ETP Commentary > 

Technology in Israel? There's an Ark ETF for That

As Israel leads the charge to per capita vaccinations, investors can consider the ARK Israel Innovative Technology ETF (IZRL).A month ago, 60% of Israelis were vaccinated, nearly double the corresponding vaccination rate of Americans at that time. Economic data suggest the benefits of a highly vaccinated population are playing out in real time.“The Bank of Israel tracks credit-card expenditure as one of its special indicators on the state of the economy during the coronavirus crisis. Through Apr. 6, expenditure was running 19% ahead of January 2020 levels,” reports Steve Goldstein for Barron’s.The Israeli Opportunity SetBeyond a stellar rate of vaccinations, there are other reasons to consider IZRL, namely Israel’s tech- and innovation-heavy economy.IZRL tracks the performance of the ARK Israeli Innovation Index, which is comprised of Israeli companies whose main business operations are causing disruptive innovation in the areas of genomics, healthcare, biotechnology, industrials, manufacturing, the Internet, or information technology, according to the issuer. The fund is one of two passively managed products offered by New York-based ARK Invest.Israel’s interest rates are at record lows. That’s a boon for tech companies with longer duration cash flows. Additionally, there are signs there’s more growth to come.“The opening of the economy and the return to normal life in Israel are expected to support continued rapid growth in the coming year,” said the Bank of Israel following its April meeting.Adding to the case for IZRL is that Israel’s GDP is forecast to grow at a rate of 6.3% this year – one of the best clips among developed economies. There’s also support from the central bank.Bank of Israel Governor Amir Yaron “also reiterated that the central bank stands by its plan to buy at least $30 billion of foreign currency in 2021 to stem the shekel’s gains. He said that whether the bank expands its bond buying programme beyond a planned 85 billion shekels ($26 billion) would be determined in the coming months,” reports Reuters.For more on disruptive technologies, visit our Disruptive Technology Channel.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.